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ABSTRAK
Nyeri hebat merupakan masalah utama bagi penderita kanker dan tatalaksana nyeri seringkali membutuhkan 
penggunaan opioid. Indonesia merupakan salah satu negara dengan penggunaan opioid yang sangat rendah 
bagi pasien kanker dan hal ini perlu mendapatkan perhatian karena banyak sekali penderita kanker di negeri 
ini mengalami penderitaan yang tak perlu mereka rasakan akibat kurangnya penggunaan opioid.
Ketidakmampuan untuk menilai nyeri dengan baik, kegagalan untuk menentukan dosis yang tepat, 
kekhawatiran akan adiksi, peraturan yang terlalu ketat, semuanya turut berperan dalam gagalnya penerapan 
penggunaan morfin yang rasional bagi penderita kanker. Nyeri lucut (breakthrough pain) merupakan masalah 
yang membutuhkan perhatian khusus, tidak hanya karena masalah ini sering dijumpai, tetapi juga karena 
dibutuhkan pengetahuan yang baik untuk menanganinya. Hambatan-hambatan tersebut dibahas dalam tinjauan 
berikut ini agar dapat memberikan pemahaman yang lebih baik tentang penggunaan opioid yang tepat bagi 
nyeri kanker yang berat. Beberapa contoh penggunaan opioid yang tidak tepat dalam tatalaksana nyeri kanker 
juga dibahas.
Kata kunci: opioid, nyeri lucut (breakthrough pain), nyeri kanker, morfin.
ABSTRACT
Severe pain is a major problem for cancer patients, and pain management often requires the use of opioids. 
Indonesia is one of the countries where the use of opioids for cancer patients is extremely low, and this calls 
for attention, as many cancer patients in the country undergo unnecessary suffering as the consequence of this 
opioid underuse.
The inability to assess pain correctly, failure to determine the correct dose, fear of addiction, overly tight 
regulation,  all contribute to the failure to implement rational use of opioids for cancer patients. Breakthrough 
pain, a problem which requires special attention not only because it is commonly found but also requires 
proper knowledge to handle them. These hurdles are discussed in the present review, in order to bring a better 
understanding about the correct use of opioids in severe cancer pain. Some examples where opiods are used 
inappropriately in cancer pain management are also discussed.
Key words: opioid, break through pain, cancer pain, morphine.
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INTRODUCTION
Pain is very commonly found in cancer 
patients.1-3 The management of cancer is 
frequently inadequate because of patients’ 
failure to report it, poor communication between 
patients and health care providers, and many 
other reasons. Severe and chronic pain often 
dehumanize dying cancer patients, causing them 
unable to pass the last segment in their live in 
serenity. Poor management for cancer pain has 
been reported frequently.4-6 Ironically in fact, 
90% cases of cancer pain can be alleviated with 
simple medical management.7 In all over the 
world, it is agreed that morphine is the opioid 
of choice to alleviate severe cancer pain.8 In 
well-developed countries such as Canada, USA, 
Denmark, Switzerland, and United Kingdom, 
the consumption of morphine for pain exceeded 
50 mg/capita in 2009. Indonesia with the annual 
consumption of only 0.054 mg/capita, belonged 
to the countries which ranked the worst in 
the world. This indicates that in Indonesia, 
opioids are extremely underused for its correct 
indications.9 Consequently, too many cancer 
patients die in pain and suffering.
The aims of the present discussion is to call 
attention for improving the use of opioids in the 
management of cancer pain in Indonesia.
BARRIERS TO USING OPIOIDS FOR CANCER 
PAIN
There are several reasons for the inadequate 
use of opioids in cancer pain. Some major 
obstacles are, among others, incompetence of the 
medical staff to assess pain, patients’ reluctance 
to express the intensity of their pain, doctors’ and 
patients’ reluctance to use opioids due to the fear 
of addiction, the insufficient skill and knowledge 
of the health care staff to use opioids for cancer 
pain.10 The fear of addiction is indeed groundless 
because when used appropriately, opioid 
addiction in cancer pain management occurs 
very rarely.11 Today, opioid-producing industries 
are striving to develop special formulations 
that deter the abuse of opioid pain killers by 
applying physical barrier, agonist/antagonist 
combinations, aversion, combination, etc.12,13 
The other hurdle, despite this is always denied 
by the regulatory authorities, is the difficulty to 
obtain morphine due to the excessively tight and 
complicated regulation. In Indonesia, PT Kimia 
Farma is authorized to import and distribute 
morphine for medical use. It is not the intention 
of the present discussion to find the culprit of 
this problem, but the poor record of opioid used 
for cancer pain in Indonesia, as reported by the 
WHO, should be improved.
PAIN ASSESSMENT
Pain is defined as an unpleasant sensory and 
emotional experience associated with actual or 
potential tissue damage, or described in terms 
of such damage (International Association 
for the Study of Pain). Inability to assess pain 
appropriately is the main cause of failure in 
management of cancer pain.14 A survey done by 
von Roenn et al,15 indicated that 76% medical 
doctors felt that they were unable to assess pain 
correctly. For various reasons, many cancer 
patients are unable to report adequately to their 
doctors the pain they feel. This is particularly true 
for the elderly, those with cognitive impairment, 
with language barrier, with drug addiction, 
or being at the end of their life.16 Cancer pain 
may include nociceptive, somatic, neuropathic, 
psychological origins or a mixture of them. 
Consequently, a holistic approach involving 
multi-disciplinary experts is often needed.
Pain assessment is done by visual analogue 
scale (VAS) method, i.e. by asking patient to 
mark a 10-cm long straight line with a pencil 
to indicate the severity of pain they feel. The 
more severe the pain, the more far to the right 
the patient has to mark. The accuracy to assess 
pain is of paramount importance for titrating the 
daily requirement of morphine. In this method 
the whole range of pain intensity is divided into 
a 10-grade scoring system. Pain scores of 1-3 
indicate mild pain and can be treated satisfactorily 
with simple analgesics (e.g. paracetamol) or non-
steroidal anti inflammatory drugs (NSAIDs) (e.g. 
ibuprofen, meloxicam, diclofenac). Pain scores 
of 4-6 should be treated with weak opioids (e.g. 
codeine, tramadol) alone or in combination 
with a simple analgesics or NSAID. Pain scores 
of 7-10 require strong opioids (e.g. morphine, 
oxycodone, hydromorphone, fentanyl). In all 
pain grades of pain, the addition adjuvants is 
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allowed as elaborated in the later part of this 
discussion.
PHARMACOTHERAPY OF PAIN
Basically, the pharmacodynamic strength 
of an analgesic should be matched to the pain 
intensity felt by the patient. This principle is 
implemented in the pain relief ladders of WHO.17 
Ladder 1 is for mild pain (pain score 1-3), which 
can be treated with simple analgesics such as 
paracetamol or NSAIDs like ibuprofen. Ladder 
2 (pain score 4-6) requires weak opioids such 
as codeine or tramadol. Some experts use a 
combination of a simple analgesic with a weak 
opioid to reduce side effect. For example, a fix 
combination of 325 mg paracetamol combined 
with 37.5 mg tramadol is available on the market. 
Ladder 3 (pain score 7-10) requires strong 
opioids such as morphine, fentanyl, oxycodone, 
etc. For patients with severe cancer pain, it is 
mandatory that strong opioids be used directly. In 
all ladders, the analgesics used may be combined 
with adjuvant(s). In a survey, it was reported 
that with proper implementation, the WHO pain 
ladder led to an 80% success rate in alleviating 
cancer pain.18
Pharmacotherapy of Cancer Pain with 
Opioids
In pharmacotherapy of severe cancer pain, 
the choice and the dose of strong opioids is 
determined in 2 phases. Phase 1 is for titrating 
the daily opioid requirement of an individual 
patient and this is best done by using intravenous 
(IV) morphine. In the Ciptomangunkusumo 
Hospital, Jakarta, the first step is to give a 
loading dose of morphine 0.05-0.1 mg/kg BW 
in 20 mL of saline solution intravenously in 3 
minutes. Usually the pain reduction effect can 
be observed in 15 minutes afterwards. Then 
the infusion is continued by giving a total daily 
dose of 10 mg/24 hours for naïve patients. A 
total daily dose of 15 mg/24 hours is given for 
opioid tolerant patients. Re-assessment of pain 
with VAS is done in 2-hour intervals. If pain 
subsides, as indicated by a reduction pain score 
of ≥3, the same dose is maintained. Otherwise, 
an additional 10% of total daily dose is given as 
an IV bolus. The additional dose may be repeated 
every 2 hours as required, but not to exceed 10 
times in 24 hours. At the end of 24 hours, the total 
daily morphine requirement can be summed up 
and be given again in the next 24 hours. If pain 
is still uncontrolled, the dose can be increased 
in the same way. If pain is controllable, the pain 
management can proceed to phase 2, where 
the daily requirement of IV morphine from a 
patient is converted to a non-parenteral opioids, 
e.g. oral morphine tablet (immediate release, 
IR, or sustained release, SR), fentanyl patch, 
hydromorphone oral, oxycodone oral, etc.
A conversion table is available for this (Table 
1). For example, a patient requires 20 mg of 
IV morphine in a day. This is converted to 60 
mg of immediate release oral morphine tablets. 
Thus, this patient needs one 10-mg tablet every 
4 hours. For patients using immediate released 
oral morphine, the last dose before bedtime could 
be doubled (i.e. 20 mg in this example) to avoid 
the patient being waken up during asleep.19,20 If 
slow release oral morphine is used in this case, 
30 mg dose is given every 12 hours. Laxative or 
stool softener should be given prophylactically 
to avoid constipation.
Table 1. Conversion table from morphine to other opioids for cancer pain
Morphine (mg/day) Codeine (mg/day) Fentanyl  (mcg/hour)
Oxycodone 
(mg/day) Hydromorphone (mg/day)
IV/SC O IV/SC O TD O IV/SC O
20 60 130 200 25 30 1.5 7.5
40 120 260 400 50 60 3 15
60 180 390 600 75 90 4.5 22.5
80 240 520 800 100 120 6 30
Note: IV = intravenous, O = oral, SC = subcutaneous, TD = transdermal. Oxycodone and hydromorphone are not yet 
marketed in Indonesia.
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Patients with well-controlled pain with an 
opioid and in stable condition may often have 2-3 
episodes of pain in a day. The pain, which lasts 
about 30 minutes, is known as a breakthrough 
pain (BP). BP occurs in 64% of patients with 
cancer pain.21 Cancer pain is considered under 
control if BP recurs not more than 3 times in a 
day. Otherwise, the daily basal requirement of 
opioid needs to be increased. Since BP has to be 
alleviated immediately, the use of a fast acting 
opioid is mandatory. Under no circumstances 
slow release opiods are indicated here. In 
hospitalized patients, one tenth of the 24-hour 
morphine is given and, if necessary, this may be 
repeated after at least 2 hours. For ambulatory 
patients who are on oral morphine, a 10-20% 
of the total daily dose is given to alleviate the 
BP. Pain is then assessed in 60 minutes, and the 
same dose is given again if there is no response. 
The European Association for Palliative Care 
recommended the use of a morphine solution 
for injection for this purpose.8 The other choice 
is fentanyl buccal soluble film (SBSF)22,23 which 
is not yet marketed in Indonesia. Anyway, slow 
release opioids such as fentanyl patch or slow 
release oral morphine should not be used to 
treat BP. 
If an opioid has been given to a patient in a 
relatively high dose but the therapeutic response 
is disappointing, several actions could be taken. 
Firstly, to perform opioid rotation because 
different opioids may have different affinity 
to various opioid receptors. Secondly, to add 
adjuvant agents (Table 2). Thirdly, to apply 
surgical intervention or radiotherapy, especially 
for pain associated with bone metastasis.
If pain disappears, e.g. because of surgical 
intervention, and opioid is no longer needed, 
then administration of opioid has to be tapered 
off within 3-5 days. In contrast, if the pain 
worsens, the dose has to be increased. Unlike 
other therapeutic agents, opioids apparently do 
not have a “ceiling effect”, which means one can 
continuously increase the dose until a desirable 
analgesic effect is obtained as long as it does 
not induce a significant side effect. Hanks et al8 
Table 2. Adjuvant analgesics for adults/children with body weight of >50 kg32
Type of drugs Dose Comment
Corticosteroids:
 - Dexamethasone 16-96 mg/day, O for pain caused by brain metastases and 
epidural spinal cord compression - Prednisone 40-80 mg/day, O
Anticonvulsants:
 - Carbamazepine 200-1600 mg/day, O for neuropathic pain
 - Phenytoin 300-500 mg/day, O
Antidepressants:
 - Amitryptilin 25-150 mg/day, O for neuropathic pain
 - Doxepine 25-150 mg/day, O
 - Imipramine 20-100 mg/day, O
 - Trazodone 75-225 mg/day, O
Neuroleptics:
 - Methotrimeprazine* 40-80 mg/day, O
Antihistaminics:
 - Hidroxyzine 300-450 mg/day, O for anxiety and nausea
Local anesthetics and antiarrhytmics:
 - Lidocaine 5 mg/KgBW/day, IV or SC for 
neuropathic pain
Psychostimulants:
 - Dextroamphetamine analgesic 5-10 mg/day, O for enhancing opioid effect reducing sedation
 - Methylphenidate 10-15 mg/day, O
IV=intravenous, O=oral, SC=subcutaneous, *=not marketed in Indonesia
Rianto Setiabudy                                                                                                                     Acta Med Indones-Indones J Intern Med
248
reported that analgesic dose of morphine may 
vary up to 1,000 times among cancer patients. 
SIDE EFFECTS
In general, opioid related side effects appear 
at the beginning of therapy and most of them 
disappear spontaneously after several days. 
Nausea, being the most frequent side effect, 
can be treated with haloperidol (1.5 mg per oral 
at bedtime), chlorpromazine (12.5 mg per oral 
every 8 hours), metoclopramide (10 mg per 
oral every 8 hours), dexamethasone (8-10 mg 
intravenously). Other commonly found side 
effects at the beginning of treatment include 
drowsiness, pruritus, and urinary retention. 
At the later stage, the prominent side effect is 
constipation. In addition to high fiber intake, 
bisacodyl (5-15 mg per oral or 10 mg per rectal) 
or lactulose (1-2 spoonful per oral) or magnesium 
hydroxide (2-4 teaspoonful before bedtime) are 
useful to overcome this problem.
A strong reason causing doctors and patients 
denying opioid treatment is the fear of addiction. 
This is groundless because, in fact, addiction 
occurs very rarely in patient with cancer pain. In 
an observational study it was reported that 7 out 
of 24.000 patients treated with opioids became 
addicted.24 There are two strong characteristics of 
addiction, i.e. compulsive reaction and craving. 
In compulsive reaction, the patient incessantly 
seeks for more opioids, regardless of the pain 
has been controlled. Craving is characterized 
by nausea, arthralgia, sweating, chilling, etc. 
at the time when an addict needs the drug. In 
the treatment of cancer pain, the increasing 
requirement of opioid may also caused by 
the progression of tumor growth rather than 
development of tolerance.
In Indonesia, meperidine (more commonly 
known as pethidine) injection is very commonly 
used, perhaps because it is widely available and 
affordable as well. In many other countries, this 
opioid has been abandoned in pain management 
because norpethidine, its major metabolite, 
stimulates the central nervous system and 
causes tremor, muscle twitching, agitation, 
and convulsion. This is more commonly seen 
if the patient gets the drug repeatedly or if the 
patient has impaired renal function.25 The toxic 
metabolite is slowly excreted out of the body due 
to its long half-life of elimination.26
PHARMACOKINETICS AND LIMITATIONS OF 
MORPHINE
Morphine has some limitations related to 
its pharmacokinetic profile. By the oral route, 
only 20-30% of a given dose is absorbed and 
its onset of action may vary considerably 
between patients.27 In patients with impaired 
renal function, one of its active metabolites, 
i.e. morphine-6-glucuronide, accumulates. This 
potent metabolite may increase morphine toxic 
effect in patients with creatinine clearance less 
than 30 mL/menit/1,73 m2).28
The non-pharmacokinetic limitation of 
morphine is its relatively poor efficacy in 
alleviating neuropathic pain (opiate insensitive 
pain). Respiratory depression is an obvious side 
effect if morphine (and other opioids) is given 
to healthy individuals, but not in patients with 
chronic cancer pain. Therefore, for patients being 
well controlled with morphine, it is important 
to reduce the dose when the pain subsides 
substantially due to e.g., surgical intervention, 
radiation, nerve block, etc.29,30 Failure to do this 
may lead to respiratory depression because the 
morphine-induced respiratory depression at the 
respiratory center is no longer opposed by pain 
transmitted from the nociceptor.31
Despite of these limitations, morphine 
remains the drug of choice for the treatment 
of cancer pain because of the accrued clinical 
experience, its wide availability, and reasonable 
cost.
COMMON ERRORS IN THE MANAGEMENT 
OF CANCER PAIN
In many cases, cancer pain cannot be 
completely eliminated. By knowing the 
commonly done errors, however, more effective 
treatment can be provided to the patients. Eight 
commonly found errors in the treatment of 
cancer pain include: 1). Failure to do appropriate 
pain assessment; 2). Mild analgesics (e.g. 
mefenamic acid) are used for severe cancer pain; 
3). Treatment for severe cancer pain is started 
with mild analgesics; 4). Slow onset of action 
opioids (e.g. slow release morphine, fentanyl 
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patch) are used to alleviate breakthrough pain; 
5). Conversion to other opiods is done before 
the daily requirement of morphine is determined 
correctly; 6). Failure to consider opioid rotation, 
adjuvant therapy, biphosphonate, and radiation 
for patients with persisting cancer pain due to 
bone metastasis; 7). Failure to anticipate opioid-
related side effects; 8). Opiod is given only when 
the patients feel pain, not around the clock.
CONCLUSION
As in many developing countries, the 
use of opioids in Indonesia to treat cancer 
pain is extremely low as compared to that 
of the developed countries – in fact, one of 
the lowests. This prompts urgent actions to 
reduce the suffering of cancer patients such 
as eliminating the myth of addiction related to 
cancer pain treatment, improving availability 
and accessibility to opioids for their proper use, 
dissemination of technique to give opioids in 
the proper dosing , and avoidance of the errors 
commonly encountered in using opioids. The 
authors would like underline a glorious tenet 
saying that freedom of pain is one of the basic 
human rights.
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